Literature DB >> 26622695

Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients.

Jian-Qiang Liu1, Xia Bai1, DE-Chen Duan1, Ai-Xia Dou2.   

Abstract

The present study aimed to investigate the association between five common small nucleotide polymorphisms (SNPs) in the VEGF gene and the risk of osteosarcoma. An additional aim was to investigate the role of these five SNPs on the prognosis of osteosarcoma. A total of 186 patients with osteosarcoma and 186 age- and sex-matched healthy controls were enrolled into the present study. A polymerase chain reaction-restriction fragment length polymorphism assay was conducted to determine the incidence of the VEGF-2578 C/A, -1156 G/A, +1612 G/A, +936 C/T and -634 G/C polymorphisms. Conditional logistic regression analyses revealed that individuals carrying the -634 GG genotype possessed a significantly increased risk of osteosarcoma, with an adjusted odds ratio [(95% confidence interval (CI)] of 2.00 (1.07-3.75). In the Cox proportional hazards model, subsequent to adjusting for potential confounding factors, patients with osteosarcoma carrying the -634 GG genotype were found to demonstrate a shorter overall survival time (hazard ratio, 3.10; 95% CI, 1.17-8.38). The VEGF-634 G/C polymorphism may therefore be used as a genetic marker for the prediction of the risk and clinical outcome of osteosarcoma.

Entities:  

Keywords:  clinical outcome; osteosarcoma; single nucleotide polymorphism; susceptibility; vascular endothelial growth factor

Year:  2015        PMID: 26622695      PMCID: PMC4533749          DOI: 10.3892/ol.2015.3396

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  37 in total

1.  Osteosarcoma derived from donor stem cells carrying the Norrie's disease gene.

Authors:  Massimo Berger; Michela Muraro; Franca Fagioli; Stefano Ferrari
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

2.  Single nucleotide polymorphisms in VEGF gene are associated with an increased risk of osteosarcoma.

Authors:  Zhang Tie; Rui Bai; Zhongwen Zhai; Gang Zhang; Hong Zhang; Zhenqun Zhao; Deshan Zhou; Wanlin Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  The molecular pathology of sarcomas.

Authors:  Martin Powers; Wei Zhang; Dolores Lopez-Terrada; Bogdan A Czerniak; Alexander J Lazar
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

5.  Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy.

Authors:  Shai-Lin Zhang; Ning-Fang Mao; Jun-Ying Sun; Zhi-Cai Shi; Bing Wang; Yong-Jian Sun
Journal:  Asian Pac J Cancer Prev       Date:  2012

Review 6.  Molecular pathology in sarcomas.

Authors:  E de Alava
Journal:  Clin Transl Oncol       Date:  2007-03       Impact factor: 3.405

7.  Association of the vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population.

Authors:  Zhen Wang; Peng Wen; Xiaojun Luo; Xiaomin Fang; Qingfeng Wang; Feng Ma; Jinhan Lv
Journal:  Tumour Biol       Date:  2013-12-06

8.  Vascular endothelial growth factor (VEGF) gene polymorphisms and colorectal cancer: a meta-analysis of epidemiologic studies.

Authors:  Zigang Zhao; Caixia Ba; Wei Wang; Xiaohong Wang; Ruizeng Xue; Xiaoting Wu
Journal:  Genet Test Mol Biomarkers       Date:  2012-09-24

9.  Combined effects of the angiogenic genes polymorphisms on prostate cancer susceptibility and aggressiveness.

Authors:  Sana Sfar; Hamadi Saad; Faouzi Mosbah; Lotfi Chouchane
Journal:  Mol Biol Rep       Date:  2007-10-05       Impact factor: 2.316

10.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

View more
  6 in total

1.  Establishment and characterization of novel patient-derived osteosarcoma xenograft and cell line.

Authors:  Fusako Kito; Rieko Oyama; Marimu Sakumoto; Mami Takahashi; Kumiko Shiozawa; Zhiwei Qiao; Hiromi Sakamoto; Takeshi Hirose; Nokitaka Setsu; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-06-25       Impact factor: 2.416

2.  Vascular endothelial growth factor polymorphisms are associated with osteosarcoma susceptibility.

Authors:  Yuan-Yuan Hu; Xin-Ya Du; Ai-Ling Zhan; Lan Zhou; Qian Jiang; Yu-Ming Niu; Ming Shen
Journal:  Oncotarget       Date:  2016-07-26

3.  Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome.

Authors:  Kuo Sun; Qi Liao; Zenggan Chen; Tongyi Chen; Jian Zhang
Journal:  Oncol Lett       Date:  2018-07-31       Impact factor: 2.967

4.  Epidemiological Evidence for Associations Between Genetic Variants and Osteosarcoma Susceptibility: A Meta-Analysis.

Authors:  Dechao Yuan; Jie Tian; Xiang Fang; Yan Xiong; Nishant Banskota; Fuguo Kuang; Wenli Zhang; Hong Duan
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

Review 5.  Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis.

Authors:  Xueyong Liu; Zhan Zhang; Chunbo Deng; Yihao Tian; Xun Ma
Journal:  Oncotarget       Date:  2017-07-19

6.  Functional variant of IL33 is associated with survival of osteosarcoma patients.

Authors:  Qingxi Lin; Jingjing Han; Qi Sun; Li Wen; Shoufeng Wang
Journal:  J Bone Oncol       Date:  2019-12-02       Impact factor: 4.072

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.